Sponsors

Tumour HER2 status assay

Ipsogen has launched MapQuant Dx HER2 test. Developed on the MapQuant Dx microarray diagnostic platform, MapQuant Dx HER2 measures a set of HER2-amplified genes that correlate with HER2 protein expression. This new HER2 test provides reliable, intelligible and decisive information for pathologists, oncologists and patients.

MapQuant Dx HER2 is the second test to be developed on the MapQuant Dx platform, after the Genomic Grade launched by Ipsogen last year. As a result of the company’s experience in molecular diagnostics and to numerous research collaborations, it aims to continue to deliver innovative tests at an accelerated pace.
www.ipsogen.com

Latest Issues

London GI Pathology Update 2026

Barbican Centre, London; and online.
28 April - 1 May

Specialist Staining – Technical Issues Master Class

The Haylofts, St Thomas Street, Haymarket, Newcastle, NE1 4LE, UK
28 April, 2026

Diagnostic Cytopathology – Beginners Master Class

The Haylofts, St Thomas Street, Haymarket, Newcastle, NE1 4LE, UK
5 May, 2026

Power to Disrupt : Leaders in POCT Diagnostics

Leonardo Royal Hotel, 245 Broad St, Birmingham, B1 2HQ
5 May, 2026

Diagnostic Cytopathology – Intermediate Master Class

The Haylofts, St Thomas Street, Haymarket, Newcastle, NE1 4LE, UK
6 May, 2026